CRESCENT BIOPHARMA, INC.
Last · NASDAQ$12.58-0.33 (-2.56%)close · yahoo · 14h ago
Market cap$467.31M37.1M sh
P/E · TTM-1.6fwd -4.8 · eps -7.63 · loss
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$8.72$27.41
Volume284.8Ksession
| Revenue | $10.8M |
|---|---|
| Operating income | $-152.6M |
| Net income | $-133.4M |
| Free cash flow | $-72.5M |
| Operating margin | -1407.5% |
| Net margin | -1230.6% |
| Return on equity | -65.7% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-26
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Medium
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 122.6%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1230.6%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -659.6%
- Cash Runway Medium — Cash runway ~3.0 years
- Rd Intensity High — R&D/Revenue 1273.4%
Press & signals
- GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
- GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
- GlobeNewswire
Crescent Biopharma Announces Grants of Inducement Awards
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans